World Health Organization Issues Alert Over Critical Shortage of Obesity Jabs
Fewer than one in 10 individuals eligible to benefit from GLP-1 drugs including Wegovy have access to them, states the WHO as it publishes its inaugural advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for increased and just availability to these injectable treatments.
According to estimates, over two billion are projected to be obese by 2030 unless action is taken.
"Our new guidance acknowledges that obesity is a chronic disease that can be addressed with comprehensive and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant obstacles to universal availability to the jabs that can assist patients in reducing substantial weight, notes the organization.
GLP-1 Therapy Supply Crisis
Despite the current most favorable outlook, the manufacturing of these medications might only reach approximately 100 million people – less than 10% of eligible patients, according to the WHO.
The guideline calls on nations and manufacturers to increase availability, via measures like voluntary licensing.
A patent on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
How Weight-Loss Jabs Work
The injections imitate a body's own hormone to slow digestion, reduce hunger and increase satiety so people reduce food intake.
Individuals commonly start to lose weight in the initial weeks of beginning the regular doses.
Studies indicates users may see weight return after a year of discontinuing the medication, as their typical hunger come back.
Being above a healthy weight raises your chance for experiencing medical conditions, like diabetes, heart disease, stroke, and specific malignancies.
Obesity concerns people in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, per the WHO.
